Glioblastoma Multiforme Therapeutics Market Size in the 7MM was found to be ~USD 900 Million in 2025 and It is projected to grow by 2036, estimates DelveInsight

DelveInsight's 'Glioblastoma Multiforme Market Insights, Epidemiology and Market Forecast- 2036' report delivers an in-depth understanding of the Glioblastoma Multiforme, historical and forecasted epidemiology as well as the Glioblastoma Multiforme market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Discover which therapies are expected to grab the Glioblastoma Multiforme Market Share @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Glioblastoma Multiforme Market Report
• According to DelveInsight's estimates, the total number of incident cases of GBM in the 7MM was nearly 38,000 cases in 2025 and is projected to increase during the forecasted period.
• The total number of incident cases of GBM in the United States was nearly 15,500 in 2025.
• In 2025, BRAF V600E mutation cases accounted for the largest share of incident GBM cases in the United States.
• The total number of cases of Primary GBM was found to be the highest than Secondary GBM in the United States and was estimated to be nearly 14,000 in 2025
• GBM is associated with a higher disease burden in men than in women. Roughly 60% of the total GBM cases in the United States are men. When compared with the adults, Glioblastoma in children is relatively rare.
• The leading Glioblastoma Multiforme Companies such as Novocure, Roche (Genentech), Merck, Daiichi Sankyo, Novartis, Bayer, Aivita Biomedical and TAE Life Sciences, Denovo Biopharma, Northwest Therapeutics and Advent BioServices, Orbus Therapeutics, TVAX Biomedical, Laminar Pharmaceuticals, Vigeo Therapeutics, Eli Lilly and Company, Incyte Corporation, Kazia Therapeutics and others
• Promising Glioblastoma Multiforme Pipeline Therapies in the various stages of development include Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.

Download the report to understand which factors are driving Glioblastoma Multiforme Epidemiology trends @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Multiforme Epidemiology Segmentation in the 7MM
• Total Incident Cases of GBM
• Gender-specific Incident Cases of GBM
• Type-specific Incident Cases of GBM
• Incident Cases based on Primary Site of GBM
• Age-specific Incident Cases of GBM
• Incident Cases based on Histologic Classification of GBM
• Unmethylation of the MGMT Gene Promoter Cases
• BRAF V600E Mutation Cases in GBM
• Line-wise Treated Pool of GBM

Discover more about Glioblastoma Multiforme Drugs in development @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Multiforme Approved Therapies
• TEMODAR/TEMODAL (temozolomide): Merck
The active pharmaceutical ingredient in TEMODAR/TEMODAL is an imidazotetrazine derivative of the alkylating agent dacarbazine. It is used for treating several brain cancer forms, e.g., as a second-line treatment for astrocytoma and a first-line treatment for GBM. The therapeutic benefit of TEMODAR is its ability to alkylate/methylate DNA. This alkylation/methylation destroys the DNA and triggers the death of the tumor cells. TEMODAR targets tumoral tissues selectively; it has an anti-neoplastic effect; it has minimum influence on adjacent brain tissues; it has no severe systemic toxicity; and it is eliminated rapidly. In March 2005, the US FDA approved TEMODAR for the treatment of adult patients with newly diagnosed GBM concomitantly with radiotherapy and then as maintenance treatment.

Glioblastoma Multiforme (GBM) Pipeline Analysis
• AV-GBM-1: Aivita Biomedical and TAE Life Sciences
AV-GBM-1 is a personalized dendritic cell-based immunotherapy developed by AIVITA Biomedical, designed to generate a broad, patient-specific immune response by targeting multiple tumor-associated antigens derived from autologous glioblastoma tumor-initiating cells. Administered as a series of subcutaneous injections, the therapy is being evaluated as an adjunct to standard-of-care treatment in newly diagnosed glioblastoma (GBM).

• Eflornithine: Orbus Therapeutics
Eflornithine (α-difluoromethylornithine, DFMO) is an irreversible inhibitor of ornithine decarboxylase, a key enzyme involved in polyamine synthesis that supports tumor cell proliferation and survival. By selectively targeting this single enzyme, eflornithine differs from multi-targeted kinase inhibitors and has demonstrated the ability to suppress tumor growth and enhance the activity of cytotoxic therapies in preclinical models, including high-grade gliomas.

Glioblastoma Multiforme Market Outlook
Unfortunately, there is no cure for glioblastoma. Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery, followed by additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. Most chemotherapy drugs are cytotoxic drugs; cytotoxic drugs are designed to destroy tumor cells and work by making them unable to reproduce. Carmustine (BCNU), Lomustine (CCNU), or Gleostine (Generic), Gliadel wafer (biodegradable discs infused with BCNU), Temozolomide (Temodar), Cisplatin, Carboplatin, Etoposide, and Irinotecan are examples of cytotoxic drugs. They may be given as a single agent or combination, i.e., PCV (Procarbazine, CCNU, and Vincristine), Carboplatin/Etoposide.

To know more about Glioblastoma Multiforme Treatment guidelines, visit @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glioblastoma Multiforme Treatment Market
Glioblastoma multiforme is typically treated with a combination of surgery, chemotherapy, radiation, or stereotactic radiosurgery. Although rarely used alone, surgery is usually one of the most important aspects of glioblastoma treatment. Because glioblastomas grow so quickly, they are frequently difficult to remove completely. As a result, surgery is performed to achieve the best possible safe resection - removing as much of the tumor as possible while preserving brain function and sparing healthy tissues. Following surgery, residual cancer cells can be targeted with additional treatments such as chemotherapy or radiation therapy. Once the tumor's diagnosis or name is determined, radiation therapy and chemotherapy are usually administered.

Glioblastoma Multiforme Market Dynamics
The Glioblastoma Multiforme Market Dynamics is predicted to change in the coming years owing to the improvement in the research and development activities so that glioblastoma multiforme market will comprise of efficient glioblastoma treatment options. Moreover, the anticipated launch of emerging therapies during the forecast period is further expected to fuel the glioblastoma multiforme market growth.

Glioblastoma Multiforme Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential Glioblastoma Multiforme drugs recently launched in the Glioblastoma market or expected to be launched during the study period. The analysis covers the Glioblastoma Multiforme market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Glioblastoma Multiforme drugs based on their sale and market share.

Learn more about the FDA-approved drugs for Glioblastoma Multiforme Treatment Market Report @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Glioblastoma Multiforme Market Report
• Coverage- 7MM
• Study Period- 2022-2036
• Forecast Period- 2026-2036
• Glioblastoma Multiforme Companies- Novocure, Roche (Genentech), Merck, Daiichi Sankyo, Novartis, Bayer, Aivita Biomedical and TAE Life Sciences, Denovo Biopharma, Northwest Therapeutics and Advent BioServices, Orbus Therapeutics, TVAX Biomedical, Laminar Pharmaceuticals, Vigeo Therapeutics, Eli Lilly and Company, Incyte Corporation, Kazia Therapeutics and others.
• Glioblastoma Multiforme Pipeline Therapies- Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, LAM561 (2-OHOA), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, VAL-083 (dianhydrogalactitol), MDNA55, Paxalisib (GDC-0084), Temferon, EO2401, INO-5401 + INO-9012 + LIBTAYO (cemiplimab), Delytact (Teserpaturev/DS-1647), TAFINLAR + MEKINIST, VBI-1901, and others.
• Glioblastoma Multiforme Market Dynamics: Glioblastoma Multiforme Market Drivers and Barriers

Request for more information of the Glioblastoma Multiforme Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Glioblastoma Multiforme Market Overview at a Glance
3. Executive Summary of Glioblastoma Multiforme (GBM)
4. Key Events
5. SWOT Analysis
6. Disease Background and Overview: Glioblastoma Multiforme (GBM)
7. Treatment
8. Treatment Algorithm
9. The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma
10. The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma
11. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions
12. SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma
13. Epidemiology and Patient Population
14. Country-wise Epidemiology of Glioblastoma Multiforme
15. Recognized Establishments
16. Patient Journey
17. Marketed Drugs
18. Emerging Drugs
19. Potential of Current Therapies and Emerging Therapies
20. Glioblastoma Multiforme: Seven Major Market Analysis
21. KOL Views
22. Market Drivers
23. Market Barriers
24. Unmet Needs
25. Market Access and Reimbursement
26. Appendix
27. DelveInsight Capabilities
28. Disclaimer
29. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.